American Urological Association Releases Incontinence after Prostate Treatment Guideline Amendment

Today, the American Urological Association (AUA), in partnership with the Society of Genitourinary Reconstructive Surgeons (GURS) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released the 2024 amendment to the Incontinence after Prostate Treatment (IPT) Guideline.  This guideline on IPT is intended to facilitate care decisions and aid clinicians in the management of patients who have incontinence after undergoing treatment for localized prostate cancer and benign prostatic hyperplasia (BPH). The multiple treatments that exist for patients with IPT are discussed, evaluated and updated within this amendment. Read more.

Source: Yahoo! Finance, June 27, 2024

mother post pregnancy

Postpartum Urinary Incontinence Linked to Mental Health

A UT Southwestern Medical Center study of hundreds of underserved women showed that depression and anxiety, in addition to physical factors such as a higher body mass index and previous births, are associated with lingering postpartum urinary incontinence. The findings, published in Urogynecology, shine a spotlight on these conditions that can carry stigmas but are largely treatable, researchers say. “Our study draws a bridge between two vital components of health care that are often overlooked and neglected: postpartum care and mental health,” said Sonia Bhandari Randhawa, M.D., a second-year Urogynecology fellow at UT Southwestern. Dr. Bhandari Randhawa co-led the study with David Rahn, M.D., Professor of Obstetrics and Gynecology at UTSW. Read more.

Source: UT Southwestern Medical Center, June 27, 2024

Atlanta-based Founder Seeks to Help Give Control for Incontinence

Urinary incontinence affects millions of women, especially those in the senior age bracket.  According to the Mayo Clinic, as many as 50% of women experience some form of leakage, and that number rises to around 75% in women over the age of 65.  The condition can cause anxiety and isolation for those who have it, but an Atlanta-based innovator is leading efforts to relieve their discomfort, and participants in the efforts she’s overseen are already reporting successes.  The company’s overall goal is to put urinary continence management more squarely in the hands of those experiencing it. We’re on a mission to give women effective, affordable, appealing alternatives to incontinence pads and surgery … to give consumers the ability to take care of these things for themselves up to a certain point,” said Melody Roberts, CEO and co-founder of Liv Labs.  A significant part of that goal lies in the success of a device the company is developing: the Pippa Pessary. Read more.

Source: Hastings Tribune, June 5, 2024

To Pee Or Not to Pee? That Is a Question for the Bladder — and the Brain

You’re driving somewhere, eyes on the road, when you start to feel a tingling sensation in your lower abdomen. That extra-large Coke you drank an hour ago has made its way through your kidneys into your bladder. “Time to pull over,” you think, scanning for an exit ramp.  To most people, pulling into a highway rest stop is a profoundly mundane experience. But not to neuroscientist Rita Valentino, who has studied how the brain senses, interprets and acts on the bladder’s signals. She’s fascinated by the brain’s ability to take in sensations from the bladder, combine them with signals from outside of the body, like the sights and sounds of the road, then use that information to act — in this scenario, to find a safe, socially appropriate place to pee. “To me, it’s really an example of one of the beautiful things that the brain does,” she says. Read more.

Source: Knowable Magazine, May 29, 2024

NorthShore Care Supply Announces Referral Program to Benefit Veterans With Disabilities

NorthShore Care Supply, the leading brand of adult diapers and absorbent products for heavy incontinence, is proud to announce its referral program in partnership with DAV (Disabled American Veterans).  This program allows existing customers to refer others to NorthShore, granting them exclusive discounts and raising money for DAV. With prices rising everywhere from the gas pump to the grocery store, people are looking for ways to save. The referral rewards program offers new customers a $10 discount on their first purchase and gives the existing customer a $10 discount off their future purchase of $100. Read more.

Source: Newswire, May 28, 2024

women friends

FDA Clears Yōni.Fit Device for Women With Stress Urinary Incontinence

The Food and Drug Administration (FDA) has cleared Yōni.Fit® Bladder Support for the temporary management of urine leakage caused by stress urinary incontinence (SUI) in women 18 years of age and older. Yōni.Fit is a self-administered, intravaginal insert that manages urinary incontinence without interfering with voluntary urination. The prescription device can be used during a specific activity or for up to 12 hours to control symptoms. Read more.

Source: Renal & Urology News, May 22, 2024

business buildings

Coloplast Expands Its Luja™ Portfolio with Next Generation Catheter for Women

The female intermittent catheter enables complete bladder emptying in one free flow, aiming to reduce the risk of urinary tract infections.  Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women.  “So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients, and seven out of ten users feel confident that it empties their bladder completely without needing to reposition the catheter4,” says Nicolai Buhl, Executive Vice President of Innovation. Read more.

Source: Globe Newswire, May 14, 2024

GRAMINEX®, L.L.C. Final Publication of a Peer Reviewed Clinical Trial with Graminex® Flower Pollen Extract Focusing on Women’s Urinary Incontinence in Current Urology

Graminex®, L.L.C. is pleased to announce publication of a peer reviewed clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health in Current Urology. The study was conducted as a randomized, double-blind, placebo-controlled study to investigate the effectiveness of Graminex® Flower Pollen Extracts in 114 healthy women with urinary incontinence.  Read more.

Source: Business Wire, May 13, 2024

nerve cells

Implantable Tibial Nerve Stimulation added as Treatment Option within AUA/SUFU 2024 OAB Guideline

Valencia Technologies is pleased to announce that implantable tibial nerve stimulation (ITNS) has been acknowledged as a minimally invasive OAB treatment option in the recently updated American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) clinical practice Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder (2024). The eCoin® ITNS device is the only fully implantable FDA PMA approved device for treating urge urinary incontinence (UUI), the primary symptom of OAB. The eCoin ITNS system commercialized in March 2022 has now been used to treat over 1,100 patients in the United States. This highlights the significant need for evolutionary treatment options to address the growing burden of a largely underserved OAB population. Read more.

Source: PRNewswire, May 2, 2024

tibial nerve

AUA/SUFU Guideline on the Treatment of Overactive Bladder Allows Access to Revi™ System Earlier in Treatment Journey

BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) and the developer of ReviTM, a patient-centric solution for urge urinary incontinence (UUI), announced today that the Revi System, a minimally invasive therapy, is now included in the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) clinical practice guideline on the diagnosis and treatment of idiopathic overactive bladder (OAB). The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI. First, the guidelines were updated to include iTNM as an acceptable minimally invasive therapy.  In addition, the revised guidelines shift away from traditional step therapy approaches, allowing physicians and patients to bypass behavioral and pharmacotherapy before considering minimally invasive therapies, including Revi.  Read more.

Source: PRNewswire, April 29, 2024